Identification of Serum miR-337-3p, miR-484, miR-582, and miR-3677 as Promising Biomarkers for Osteosarcoma.

BACKGROUND

The present study aimed to elucidate the clinical values of miR-337-3p, miR-484, miR-582, and miR-3677 in patients with osteosarcoma.

METHODS

After extracting RNA from serum samples of healthy volunteers, OS patients, and periostitis patients, the real-time quantitative polymerase chain reaction (RT-qPCR) analysis was carried out. Afterwards, the receiver operating characteristic (ROC) assays were conducted in order to identify the area under the curves of certain microRNAs in OS. Finally, the log-rank survival analysis was used to analyze the five-year survival rate and disease-free survival rate of OS patients with aberrant microRNA expressions.

RESULTS

From the results, miR-337-3p, miR-484, miR-582, and miR-3677 were remarkably decreased in OS cell lines, tumor tissues, and serum samples of OS patients. Furthermore, receiver operating characteristic (ROC) analysis verified that serum miR-337-3p, miR-484, miR-582, miR-711 and miR-3677 had favorable diagnostic values for identifying OS from periostitis patients with the area under the curves of 0.9434, 0.8760, 0.717,0 and 0.8705 and from healthy volunteers with the area under the curves 0.8218, 0.8358, 0.8008, and 0.7141, respectively. After surgery, serum miR-337-3p, miR-484, miR-582, and miR-3677 were dramatically increased. Meanwhile, lower expressions of miR-337-3p, miR-484, miR-582 and miR-3677 were strongly correlated with clinical stage and metastasis. Last but not the least, the log-rank survival analysis demonstrated that lower expressions of miR-337-3p, miR-484, miR-582, and miR-3677 were related to unfavorable prognosis in OS patients.

CONCLUSIONS

Our study verified and illustrated the clinical values of miR-337-3p, miR-484, miR-582, and miR-3677 for the detection and prognosis of OS.